A Phase Ib clinical trial to evaluate the safety, tolerance and preliminary immunogenicity of different doses of a SARS-CoV-2 mRNA vaccine in population aged 18-59 years
Latest Information Update: 02 Dec 2020
At a glance
- Drugs ARCoV (Primary)
- Indications COVID-19 pneumonia
- Focus Pharmacodynamics
- 02 Dec 2020 New trial record
- 22 Oct 2020 According to a Chinese Clinical Trial Register record, recruitment completion is expected by 30 November 2020.